New hope for kids with rare kidney disease: crovalimab trial underway
NCT ID NCT04958265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests crovalimab in 41 children with atypical hemolytic uremic syndrome (aHUS), a rare disease that causes blood clots and kidney damage. The drug is given first through a vein, then as a shot under the skin every four weeks. The goal is to see if it can stop disease flares and improve kidney function. Because aHUS is a chronic condition, treatment is expected to be lifelong.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Crovalimab (a drug given by IV and then by injection under the skin)
What this could lead to
If it works, this could offer a new treatment option for children with aHUS, helping control the disease and protect kidney function.
What could go wrong
This is a single-arm, open-label study with no comparison group, so results may be less certain. The drug requires lifelong use and carries infection risks, including meningitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Children?s Health and Medical Center
Aichi, 474-8710, Japan
-
All India Institute Of Medical Sciences (AIIMS)
New Delhi, National Capital Territory of Delhi, 110029, India
-
Beijing Children's Hospital, Capital Medical University
Beijing, 100045, China
-
CHU Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
Chiba Children's Hospital
Chibashi, Chibaken, 266-0007, Japan
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Gh Necker Enfants Malades
Paris, 75743, France
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hospital de Especialidades Puerta de Hierro S.A de C.V.
Zapopan, 45116, Mexico
-
Hôpital Arnaud de Villeneuve
Montpellier, 34295, France
-
Inst. Da Criança- Faculdade de Medicina Usp
São Paulo, São Paulo, 05403-900, Brazil
-
Institute of Kidney Diseases and Research Centre
Ahmedabad, Gujarat, 380016, India
-
Instytut ?Centrum Zdrowia Matki Polki
Lodz, 93-338, Poland
-
Medanta-The Medicity
Gurgaon, Haryana, 122001, India
-
Peking University First Hospital
Beijing, 100034, China
-
The children's hospital , Zhejiang university school of medicine
Hangzhou, 310051, China
-
UZ Gent
Ghent, 9000, Belgium
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
University of Nebraska
Omaha, Nebraska, 68198, United States
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-294, Poland